Elevated serum levels of S100 and survival in metastatic malignant melanoma

被引：74

作者：

Buer, J

Probst, M

Franzke, A

Duensing, S

Haindl, J

Volkenandt, M

Wittke, F

Hoffmann, R

Ganser, A

Atzpodien, J

机构：

[1] HANNOVER MED SCH,DEPT HAEMATOL & ONCOL,D-30623 HANNOVER,GERMANY

[2] HANNOVER MED SCH,DEPT NUCL MED,D-30623 HANNOVER,GERMANY

[3] UNIV MUNICH,DEPT DERMATOL,D-8000 MUNICH,GERMANY

来源：

BRITISH JOURNAL OF CANCER | 1997年 / 75卷 / 09期

关键词：

S100; metastatic malignant melanoma; multivariate analysis of survival; prognosis;

D O I：

10.1038/bjc.1997.232

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Current reports suggest serum S100 as a prognostic marker for disease progression in advanced malignant melanoma. In this study, we assessed serum levels of S100 and multiple clinical factors in relation to overall survival in 99 patients with metastatic malignant melanoma seen at our institution between May 1990 and April 1996. For statistical analysis, we used both univariate and multivariate Cox proportional-hazards models. Elevated serum levels of S100 correlated with poor outcome in metastatic malignant melanoma (P < 0.0001), univariate analysis). Upon multivariate analysis, however, S100 added no information to known clinical prognostic parameters.

引用

页码：1373 / 1376

页数：4

共 21 条

[11] NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].